Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis
Raquel Sainz-Amo(Instituto de Salud Carlos III), Luisa María Villar(Evidence (Italy)), Jaime Masjuán(Universidad de Alcalá), Enric Monreal(Hospital Universitario Ramón y Cajal), José Ignacio Fernández-Velasco(Hospital Universitario Ramón y Cajal), Noelia Villarrubia(Universidad de Alcalá), Lucienne Costa‐Frossard(Universidad de Alcalá), José Luis Veiga González(Instituto de Salud Carlos III), Juan Luis Chico García(Instituto de Salud Carlos III), Fernando Rodríguez Jorge(Instituto de Salud Carlos III), Alexander Rodero Romero(Instituto de Salud Carlos III)
Cited by 10
Related Papers
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study
|European Journal of Neurology|2020|385